Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma

Cell Cycle. 2018;17(11):1310-1318. doi: 10.1080/15384101.2018.1480208. Epub 2018 Jul 25.

Abstract

Testis expressed 10 (Tex10), a new core component of the pluripotency circuitry, has been reported to positively regulate embryonic stem cell (ESC) super-enhancers to promote ESC self-renewal; however, the expression and function of Tex10 in hepatocellular carcinoma (HCC) and liver cancer stem cells remains unclear. The present study was designed to investigate the expression patterns of Tex10 with immunohistochemistry, western blotting and RT-qPCR in samples from HCC patients and HCC cell lines. The results obtained show that Tex10 was highly expressed in HCC tissues, and elevated Tex10 protein levels positively correlate with the poorly differentiated carcinoma. Likewise, we found that Tex10 expression in the high-metastasis HCCLM3 potential cell line was higher than that in the low-metastasis HepG2 potential cell line, and Tex10 expression in liver cancer stem cells was also higher than that in adhered HCC cells. In addition, Tex10 knockdown decreased stem cell marker expression and drug resistance. Tex10 promoted cancer stemness through activation of the STAT3 signaling pathway. Taken together, our study demonstrates that Tex10 plays a potent carcinogenic role in HCC tumorigenesis by maintaining cancer stem cell properties through activation of the STAT3 signaling pathway and promoting chemo-resistance. Thus, targeting Tex10 may provide a novel and effective therapeutic strategy to suppress the tumorigenicity of advanced HCC.

Keywords: Hepatocellular carcinoma; STAT3 signaling; Tex10; cancer stem cell; chemoresistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / pathology
  • Cell Cycle / drug effects
  • Cell Differentiation
  • Cell Line, Tumor
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Drug Resistance, Neoplasm* / genetics
  • Humans
  • Hyaluronan Receptors / metabolism
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / genetics*
  • Liver Neoplasms / pathology
  • Mice
  • Neoplasm Metastasis
  • Neoplastic Stem Cells / metabolism*
  • Neoplastic Stem Cells / pathology*
  • Nuclear Proteins / genetics*
  • Nuclear Proteins / metabolism
  • Phenotype
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction / drug effects
  • Sorafenib / pharmacology
  • Sorafenib / therapeutic use
  • Up-Regulation* / genetics

Substances

  • Hyaluronan Receptors
  • Nuclear Proteins
  • STAT3 Transcription Factor
  • TEX10 protein, human
  • Sorafenib
  • Cisplatin

Grants and funding

This work was supported by the Key Project of Education Department of Sichuan Province [16ZA0235]; Bureau of Science & Technology and Intellectual Property Nanchong City [NSMC20170466,16YFZJ0031]; Health and Family Planning Commission of Sichuan Province [17PJ487,17PJ503] Innovation Team Project of Sichuan Provincial Education Department [13TD0030].